Pfizer leans on cost cuts to offset falling revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
JPMorgan Reiterates Neutral Rating on Pfizer (PFE)
April 29, 2025 4:14 PM EDTJPMorgan analyst Chris Schott reiterated a Neutral rating and $30.00 price target on Pfizer (NYSE: PFE).
The analyst comments "Exiting PFEs 1Q results and our follow up with the company, we want to provide our key takeaways. On the qtr, PFE's sales came in below expectations (which is not surprising as... More
